Evaluating the economic burden of psoriasis in the United States
Evaluating the economic burden of psoriasis in the United States
复制标题
DOI：
10.1016/j.jaad.2015.02.1099
复制
发表时间：
2015-06-01
影响因子：
13.8
通讯作者：
Lebwohl, Mark
中科院分区：
文献类型：
--
作者：
Vanderpuye-Orgle, Jacqueline;Zhao, Yang;Lebwohl, Mark
背景：银屑病对患者有显著的经济影响。然而，其总的经济负担还没有完全quantitatives.Objectives：评估银屑病的年度经济负担在美国。方法：进行了系统的文献回顾，以获得估计银屑病的经济负担的组成部分。患病率估计用于估计2013年银屑病人群。增量医疗费用是根据比较银屑病患者和对照组的研究计算的。生产力损失估计使用出勤率，缺勤率和失业的措施。减少健康相关的生活质量（HRQOL）计算从调查results.Results：银屑病在美国的患病率估计为740万，在2013年。相比之下，银屑病患者的医疗费用增加了2284美元，HRQOL下降了2203美元，生产力下降了1935美元。银屑病的总负担估计为352亿美元，其中增加的医疗费用为122亿美元（35%），HRQOL降低为118亿美元（34%），生产力损失为112亿美元（32%）。局限性：本研究受到现有文献范围和人群的限制。牛皮癣在美国的经济负担是显着的，其中大部分来自间接成本。
Background: Psoriasis has significant economic impact on patients. However, its total economic burden has not been fully quantified.Objectives: To assess the annual economic burden of psoriasis in the United States.Methods: A systematic literature review was conducted to obtain estimates of the components of the economic burden of psoriasis. Prevalence estimates were used to estimate the 2013 psoriasis population. Incremental medical costs were calculated based on studies that compared psoriasis patients and controls. Productivity loss was estimated using measures of presenteeism, absenteeism, and unemployment. Reductions in health-related quality of life (HRQOL) were calculated from survey responses.Results: The prevalence of psoriasis in the US was estimated to be 7.4 million in 2013. Comparatively, psoriasis patients incurred incremental medical costs of $2284, experienced a $2203 reduction in HRQOL, and a $1935 reduction in productivity. The total burden of psoriasis was estimated as $35.2 billion, with $12.2 billion in incremental medical costs (35%), $11.8 billion from reduced HRQOL (34%), and $11.2 billion from productivity losses (32%).Limitations: This study is constrained by the scope and populations of the existing literature.Conclusions: The economic burden of psoriasis in the US is significant, with a majority of it coming from indirect costs.